Search Results

epsilon gamma delta beta thalassaemia a rare cause severe anaemia newborns dr shirley henderson red cell sig 24th september bbts annual conference harrogate 2014 haemolytic disease born rh d allo immunisation abo incompatiblity rbc allo immunisation rbc membrane disorders hs hpp rbc enzyme defects g6pd pk others haemoglobinopathies alpha thalassaemia major unstable structural variants thalassaemia normal haemoglobins hb a 2 2 95 total b 2 2 2 3 2 total hb f 2 2 predominant hb babies 1 0 adults g

haemoglobinopathy patient genotyping optimising clinical care kirstin finning international blood group reference laboratory nhs blood transplant filton background nhsbt mission statement to save improve lives includes haemoglobinopathy patient genotyping initiative inherited diseases collectively known haemoglobinopathies include sickle cell disease scd thalassemia 10 000 people sickle cell disease 800 thalassaemia majority patients receive exchange red cell transfusion therapy multiple occasio

an update proposed edition jacie cell processing presented dr claire wiggins 24th september 2014 th 6 sci southampton national blood service introduction review process commenced mid june 2013 standards committee 3 sub committees clinical collection processing sub committee fact jacie representatives sci southampton national blood service introduction continued teleconferences started end summer 2013 every 2 weeks mid december standards committee met 24th feb edition published april 2014 public

the role quality manager stem cell transplantation university hospitals leicester sarah ward my background 20 years experience a biomedical scientist haematology blood transfusion head hunted transplant director started stem cell lab quality manager june 2009 trust re organisation 2012 resulted role changing uhl ngh transplant programme quality manager january 2014 uhl ngh transplant programme main site leicester royal infirmary lri autologous transplants northampton general hospital ngh adult a

engineered t cell therapies cancer critical parameters clinical success gavin bendle llr bennett senior fellow school cancer sciences university birmingham overview engineered t cell therapies cancer conceptual basis tcr car gene transfer clinical experience safety concerns critical parameters clinical success conceptual basis engineered t cell therapy cancer immunological tolerance impairs t cell immunity cancer t cells strongly reactive self antigens self tolerance mechanisms central periphera